PharmaEngine

PharmaEngine Diluted EPS

The Diluted Earnings per Share of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 2.70 TWD. In the previous year, Diluted Earnings per Share was 12.19 TWD — a change of -77.86% (lower).

Diluted EPS

2.70TWD

YoY

-77.86%

Last updated:

Diluted Earnings per Share of PharmaEngine is 2025 2.70 TWD. Diluted Earnings per Share of PharmaEngine was 2024 12.19 TWD. It decreases by -77.86% lower compared to the previous year.

The PharmaEngine Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
0.87 TWD
Jan 1, 2019
0.29 TWD
Jan 1, 2020
4.27 TWD
Jan 1, 2021
2.97 TWD
Jan 1, 2022
2.22 TWD
Jan 1, 2023
1.91 TWD
Jan 1, 2024
12.19 TWD
Jan 1, 2025
2.70 TWD
The PharmaEngine Diluted EPS history
YEARDiluted EPSYoY
2.70TWD-77.86%
12.19TWD+537.25%
1.91TWD-13.79%
2.22TWD-25.32%
2.97TWD-30.49%
4.27TWD+1,385.69%
0.29TWD-67.00%
0.87TWD-59.92%
2.17TWD-53.86%
4.71TWD+75.93%
2.68TWD+212.69%
0.86TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Diluted Earnings per Share of PharmaEngine is 2.70 TWD in 2025.

Diluted Earnings per Share of PharmaEngine changed from 12.19 TWD to 2.70 TWD, representing a -77.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaEngine

All Key Metrics — PharmaEngine